Skip to content

To compare PK/PD study of Insulin aspart injection I. P. 100 units/mL of G. C Chemie Pharmie Limited, India comparing with NovoRapid 100 units/ml solution for injection of Novo Nordisk in Healthy male subjects.

A double blind, balanced, randomized, two-treatment, two-sequence, two period, single dose, crossover, pharmacokinetic and pharmacodynamic bioequivalence research of insulin aspart injection I. P. 100 units/mL of G. C Chemie Pharmie Limited, India comparing with NovoRapid 100 units/ml solution for injection of Novo Nordisk A/S, Novo All , DK-2880 Bagsvaerd, Denmark, in healthy, adult, human male participants using Euglycemic clamp technique under fasting conditions. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112917
Enrollment
26
Registered
2026-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Insulin aspart injection I. P. 100 units/mL: Dose: 0.2 IU/kg Frequency: Single dose Route of administration: subcutaneous Duration of the study: Total expected duration of the researc

Sponsors

G. C. Chemie Pharmie Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy human male participants between 18-45 years of age (including both). 2.Participants who are able to communicate effectively. 3.Normal range for OGTT. 4.Truly voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Participants having history of contraindication or hypersensitivity (e.g., anaphylaxis) to Insulin or related class of drugs will be excluded from the research. 2. A history or presence of significant asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. 3. History or presence of diabetes, migraine, hypertension, cardiovascular, pulmonary, endocrine, immunological, hepatic, renal, hematopoietic, gastrointestinal, ongoing infectious diseases, or any other significant abnormality as evidenced by medical history and physical examination or according to the opinion of the physician. 4. History or presence of gastrointestinal (GI) inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine. 5. History or presence of significant systemic diseases, seizures, psychiatric disorders, neurological disorders. 6. History of diabetic ketoacidosis 7. History of hypoglycaemia (symptoms include low pulse rate, watering of extremities, dizziness, weakness and sometimes fainting) 8. History or evidence of exfoliative dermatitis, Stevens - Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). 9. Any known enzyme inducing or inhibiting drug taken within 30 days before the research. 10. Participation in a drug research research within 90 days prior to dosing of this research. 11. Blood loss or whole blood donation within 90 days prior to drug administration. 12. Consumption of high caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/beedies/cigars per day). 13. History of addiction to any recreational drug or drug dependence. 14. An unusual or abnormal diet, for whatever reason within 48.00 hours prior to admission of each period, e.g., fasting due to religious reasons. 15. History of dehydration from diarrhea, vomiting or any other reason within a period of 48.00 hours prior to research admission of each period. 16. Positive results for drugs of abuse (benzodiazepines, cocaines, opioids, amphetamines, cannabinoids and barbiturates) in urine during the admission of each research period. 17. Positive results for alcohol consumption during the admission of each research period. 18. History of pre-existing bleeding disorder. 19. Difficulty with donating blood. 20. Difficulty in swallowing oral solids like tablets / capsules. 21. Blood pressure on the day of admission of each research period a. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg. b. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg. 22. Pulse rate less than 60 beats/minute or more than 100 beats/minute on the day of admission of each research period. 23. History of alcohol abuse and/or dependence within six months of the screening visit or History of drug abuse or use of illegal drugs within 90 days prior to dosing of this research.

Design outcomes

Primary

MeasureTime frame
Primary PK Parameter: INS-AUC0-t, INS-AUC0-inf, and Cmax Primary variables: GIR-AUC0-12and GIRmaxTimepoint: 0-12 Hours

Secondary

MeasureTime frame
Secondary PK Parameter: Tmax , t1/2 & Kel Secondary PD Parameter: TGIRmaxTimepoint: 0-12 Hours

Countries

India

Contacts

Public ContactVenkatasubbaiah Narra

ADVITY Research Pvt. Ltd.

vasudev.sureddy@advityresearch.com4069089999

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026